详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials

79| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [2]Division of Nutrition, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [3]Key Laboratory of Organ Transplantation, Ministry of Education, Chinese Academy of Medical Sciences, Wuhan, China. [4]NHC Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.

出处：

DOI：

ISSN：

关键词： non-alcoholic fatty liver disease gut microbiota gut-liver axis probiotics randomized clinical trial

摘要：

Non-alcoholic fatty liver disease (NAFLD) is a global public health issue, of which the prevalence is about 25% worldwide. The incidence of NAFLD is increasing in patients with obesity, type 2 diabetes (T2DM) and the metabolic syndrome. The crosstalk between gut microbiota and metabolism-related diseases has been raised great concern. Patients with NAPLD were observed with disruption of gut microbiota. Several researches showed that gut microbiota was the determination in the progression of NAFLD by the experiments using fecal microbiota transplants. The application of probiotics, as one of the most important strategies for the regulation of gut microbiota disorder, have been explored whether it is beneficial to gut-related diseases of intestine-distal organs. Some probiotics were showed to improve the liver parameters and phenotype in patients with NAFLD. The oral intake of them might become the effective management for the prevention and treatment of NAFLD. In this review, we summarized the human clinical trials focusing on the effects of probiotics on NAFLD to give some evidential reference for the administration of NAFLD.Copyright © 2023 Cao, Shi, Wang, Yao and Zeng.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区农林科学

小类 | 2 区营养学

最新[2025]版：

大类 | 2 区农林科学

小类 | 3 区营养学

JCR分区：

出版当年[2021]版：

Q1 NUTRITION & DIETETICS

最新[2023]版：

Q2 NUTRITION & DIETETICS

影响因子： 4 最新[2023版] 4.4 最新五年平均 6.59 出版当年[2021版] 6.873 出版当年五年平均 6.576 出版前一年[2020版] 5 出版后一年[2022版]

第一作者：

第一作者单位： [1]Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

通讯作者：

通讯机构： [1]Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [2]Division of Nutrition, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [3]Key Laboratory of Organ Transplantation, Ministry of Education, Chinese Academy of Medical Sciences, Wuhan, China. [4]NHC Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges [2]Non-alcoholic fatty liver disease derails antiviral immunity in murine viral hepatitis [3]Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake [4]Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice [5]Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities [6]Maternal One-Carbon Supplement Reduced the Risk of Non-Alcoholic Fatty Liver Disease in Male Offspring [7]Research Progress of Fecal Microbiota Transplantation in Liver Diseases [8]Osr1 regulates hepatic inflammation and cell survival in the progression of non-alcoholic fatty liver disease [9]The nuclear and cytoplasmic roles of miR-320 in non-alcoholic fatty liver disease [10]The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease